Jason Damiano

Jason Damiano is currently the Chief Scientific Officer at Appia Bio, where Jason focuses on creating allogeneic cell therapies for oncology and autoimmune disease. With a background in oncology biological therapeutics, Jason has experience in leading global drug discovery projects and developing novel technologies in the biotech industry. Prior to their current role, Jason held various leadership positions at companies such as UNITY Biotechnology, Achaogen, and Novartis, contributing to the discovery and development of therapeutic antibodies and small molecules for different disease indications. Jason's expertise also extends to immuno-oncology target identification and ADC discovery, showcasing their diverse skill set in the field.